AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-13
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(0) · ALS(1) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(1) · Multiple sclerosis(1) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
No new qualifying paper for this issue.
ALS: treatment, trials and AI
- Abstract
We developed a novel machine learning model named performance-weighted ensemble learning (PWEL) to detect frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) using speech from word and sentence reading tasks. Overall, 197 participants (30 with FTD, 74 with ALS, and 93 healthy controls) were enrolled. The brief oral reading tasks consisted of 16 materials adapted from the Western Aphasia Battery and took 1 min to complete. For each task, 405 speech features (i.e., 384 acoustic, 17 linguistic, and 4 temporal) were extracted. Five-fold cross-validation highlighted acoustic features—especially Mel-Frequency Cepstral Coefficients—as key discriminators of FTD and ALS from healthy controls. PWEL, which included under-bagging and adaptive task selection, achieved an area under the curve of 0.840, a sensitivity of 0.828, and an overall accuracy of 0.792. The sensitivity for FTD subtypes was 0.700–0.933, and that for ALS reached 0.812. Our proposed model surpassed both a simple ensemble learning model and task-wise classification in overall sensitivity, accuracy, and macro-F1. Its internal robustness was supported by consistent performance across stratified cross-validation folds and three recording sites. In conclusion, PWEL is practical, scalable, and making it a promising tool for detecting neurodegenerative disorders.
Journal IF-equivalent: 6.3 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-10; not the official Clarivate IF)Reference: Ito Y, Ohdake R, Kato S, Masuda M, Suzuki M, Watanabe H, et al. Performance-weighted ensemble learning for detecting patients with FTD and ALS from short reading tasks. Sci Rep. 2026 Nov 11 [Epub ahead of print]. doi:10.1038/s41598-026-73857-1.Checked: Abstract only
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
Introduction: Multimodal deep learning has been proposed as a low-cost method for early screening of Parkinson's disease (PD), with most recent frameworks reporting accuracies exceeding 96% using k-fold cross-validation instead of a single fixed train/test partition.
Methods: We introduce ParkFuse, a trust-gated late-fusion framework that assigns each modality a matched representation-classical learned acoustic descriptors for voice, geometric stroke and tremor descriptors for handwriting, and residual convolutional networks for images-combined through soft-voting late fusion. Out-of-fold predictions are obtained via stratified, grouped k-fold cross-validation, and a quantitative shortcut audit tests whether classes are separable by trivial acquisition properties alone, yielding a trust gate that excludes leakage-suspect modalities from fusion.
Results: On a public 10-modality PD dataset, the audit reveals that imaging modalities achieve a near-optimal train-validation gap, whereas the electrocardiogram (ECG) folder contains files that are byte-identical across both classes-a signature of leakage rather than disease. In contrast, sustained-vowel voice recordings remain the strongest valid predictor (achieving out-of-fold AUCs of 0.98 and 0.96). A controlled ablation study shows that modality-matched features outperform a uniform image-style network on voice and drawing by as much as 0.43 in AUC. Discussion We argue that headline multimodal PD accuracies must always be reported alongside leakage diagnostics and that voice remains the most trustworthy modality for screening.
Journal IF-equivalent: 3.4 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Oli NM, Rahman A, Aziz AKMRB, Dutta S, Kader A, Sharfuddin M, et al. ParkFuse: a trust-gated late-fusion framework with shortcut auditing for multimodal Parkinson’s disease detection. Front Med. 2026 Nov 11;13:1905869. doi:10.3389/fmed.2026.1905869.Checked: Abstract only - Abstract
BACKGROUND: Early and accurate diagnosis of Parkinson's disease (PD) remains challenging due to clinical overlap with other parkinsonian syndromes. DaTscan single-photon emission computed tomography (SPECT) is widely used during diagnosis; however, a subset of clinically diagnosed patients presents scans without evidence of dopaminergic deficit (SWEDD), creating diagnostic ambiguity. This study developed and validated a deep learning (DL)-based multiclass framework to distinguish PD, SWEDD, and normal controls using DaTscan SPECT images. METHODS: DaTscan images from the Parkinson's Progression Markers Initiative (PPMI) were used for model development, with external validation performed using an independent cohort from Chiayi Christian Hospital. AlexNet, EfficientNet-B0, and Vision Transformer (ViT) architectures were trained and evaluated using accuracy, precision, recall, and F1-score. The best-performing model was integrated into an automated diagnostic tool, the Parkinson's Disease Detector App. RESULTS: EfficientNet-B0 achieved the highest accuracy for three-class classification on the PPMI dataset (94.2%), outperforming ViT (92.0%) and AlexNet (89.5%). External validation demonstrated strong generalizability (accuracy 92.4%, F1-score 95.8%). The diagnostic app achieved 90.6% accuracy in distinguishing PD and SWEDD from controls. CONCLUSION: The proposed DL framework enables accurate multiclass classification of DaTscan SPECT images and shows promise as an objective adjunct for PD diagnosis. Multicenter validation is warranted.
Journal IF-equivalent: 2.0 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Kenneth MJ, Hsu YL, Cheng CY, Mukundan A, Hsieh MC, Lai LM, et al. Enhancing diagnosis of Parkinson’s Disease through a deep learning–based multiclass interpretation of DaTscan SPECT images. Psychiatry Res Neuroimaging. 2027 Mar;365:112385. doi:10.1016/j.pscychresns.2026.112385. PMID: 43014087.Checked: Abstract only
See all 2 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
- Abstract
Given heterogeneous progression of Duchenne muscular dystrophy (DMD), accurately characterizing individual disease trajectories is critical for effective clinical trials and therapeutic development. In this study, we applied machine learning (ML) approaches leveraging disease progression models and baseline magnetic resonance (MR)-derived radiomic features to quantify individual-level DMD progression trajectories and support quantitative characterization of disease progression. Radiomic features were extracted from segmented soleus (SOL) and vastus lateralis (VL) fat-fraction maps, generating 810 features per individual, with additional functional and demographic measures incorporated as covariates following feature selection. Multiple ML regressors were trained and validated to estimate MR-spectroscopy fat-fraction trajectory descriptive parameters: DPT 50 (age at half-maximal increase), DP max (extent), γ (rate), S 0 (extrapolated measure at age 0). Key radiomic features were identified through feature importance analyses, followed by downstream analyses, including unsupervised clustering. The tree-based XGBoost regression model demonstrated best future longitudinal fat-fraction trajectories (SOL: mean absolute error (MAE) = 0.04, R 2 = 0.94; VL: MAE = 0.06, R 2 = 0.95). Subsequent downstream analyses highlighted potential key biomarkers clinically associated with DMD progression. Clustering analysis revealed clinically meaningful slow- and fast-progression subgroups with interpretable decision criteria (SOL: DPT 50 = 12.21 vs. 14.83; γ = 8.07 vs. 7.54, VL: 10.37 vs. 14.21; γ = 7.72 vs. 7.09) that can inform clinical trial designs and therapeutic effects within homogenous groups. Individual-level feature importance interpretation further shows the possibility of tailoring personalized intervention strategies. These findings highlight the potential of ML-based trajectory modeling approaches leveraging baseline MRI radiomics for advancing AI-assisted clinical trial development and precision medicine, charting a new direction for MRI-guided disease modeling in neuromuscular disorders.
Journal IF-equivalent: 4.9 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Jeong H, Willcocks RJ, Walter GA, Mueller RA, Sanabria FM, Triplett WT, et al. Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics. Clin Pharmacol Ther. 2026 Nov 11 [Epub ahead of print]. doi:10.1002/cpt.70558. PMID: 43010800; PMCID: PMC13752581.Checked: Abstract only
See all 1 Neuromuscular papers →
Multiple sclerosis: treatment, trials and AI
- Abstract
BACKGROUND: Early diagnosis and intervention are crucial in multiple sclerosis (MS), yet diagnostic delays are common. Large language models (LLMs) such as generative pre-trained transformers (GPTs) may streamline diagnostic workflows by extracting MS diagnostic signals from clinical notes. OBJECTIVE: To derive MS diagnosis status from the first neurology note using a computable algorithm based on the 2017 McDonald criteria and applying GPT-4 for node-level reasoning within a structured decision framework. METHODS: We analyzed the first neurology notes from 125 randomly selected patients (people with MS, related disorders, and controls) enrolled in a clinic-based cohort between 2017 and 2023. We included the clinical history and diagnostic testing sections but redacted the assessment and plan. We converted the 2017 McDonald criteria into a decision tree and provided expert-curated clinical knowledge to guide GPT-4 reasoning at each decision node. GPT-4 generated binary decisions at each node to traverse the tree and assign MS diagnoses at terminal nodes. We evaluated performance against neurologist-assessed diagnoses and characterized hallucination types (non-factual, incongruent, irrelevant, over-reliant, and logical reasoning errors). RESULTS: In this study cohort (mean age 40±12 years; 81% women) representative of the clinic population, GPT-4 performed well in predicting MS diagnosis (84% accuracy, 79% precision, 74% recall, 91% specificity) using first neurology notes. Hallucinations occurred in 32 cases (26%), most commonly incoherence (75%) and overreliance (47%). CONCLUSION: A structured, LLM-guided decision framework can identify MS diagnoses from early clinical documentation. Large-scale studies are needed to mitigate hallucinations, validate this approach, and test implementation in clinical settings.
Journal IF-equivalent: 2.6 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Venkatesh S, DelSignore M, Wu X, Morris M, Kerr WT, Visweswaran S, et al. Large language model–enhanced decision tree framework for identifying multiple sclerosis diagnoses from clinical documentation. Mult Scler Relat Disord. 2027 Jan;117:108024. doi:10.1016/j.msard.2026.108024. PMID: 43014132.Checked: Abstract only
See all 1 Multiple sclerosis papers →
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.